Skip to content

Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes

Dealing With Anxiety: A Pilot Cognitive Behavioural Program for Diabetic Clinic Outpatient Attendees

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00659932
Enrollment
64
Registered
2008-04-17
Start date
2002-05-31
Completion date
2005-03-31
Last updated
2008-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2

Keywords

diabetes, cognitive behavioural therapy

Brief summary

This study was designed to assess whether a cognitive behavior therapy (CBT) program for diabetes clinic patients was acceptable, improved quality of life and produced measurable change in levels of depression, anxiety and stress.

Detailed description

Having co-morbid anxiety or depression makes it difficult to carry out the activities for diabetes selfcare. Psychological interventions have been shown to result in improvements in HbA1C and depression. Reports on psychosocial outcomes are conflicting and there are no studies of quality of life. Our diabetes outpatient population has a higher prevalence of anxiety and depression compared to the general public and this led to the development of a group CBT intervention designed to reduce anxiety as a co-morbidity of diabetes.

Interventions

BEHAVIORALImmediate Cognitive behavioural therapy (CBT)

The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period

BEHAVIORALDelayed CBT

Commencement of the CBT Group Program is delayed 3 months

Sponsors

Hunter and New England Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Consenting attendees of the Hunter Area Diabetes Services RNH Diabetes Outpatient Clinic

Exclusion criteria

* Accessibility problems including: * limited English * developmental disability * physical immobility * geographical distance * extreme age/frailty

Design outcomes

Primary

MeasureTime frame
Hemoglobin A1C (HbA1C)6 months

Secondary

MeasureTime frame
Depression Anxiety Stress Scale (DASS)6 months
Diabetes Quality of Life (ADDQoL)6 months

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026